Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert Bermel

Showing results (11-20 of 25) with videos related to

Pageof 3
Sort By:
Multiple Sclerosis (Houndmills, Basingstoke, England)|January 28, 2021
Characterisation of MS phenotypes across the age span using a novel data set integrating 34 clinical trials (NO.MS cohort): Age is a key contributor to presentationFrank Dahlke, Douglas L Arnold, Piet Aarden, et al.
American Journal of Alzheimer'S Disease and Other Dementias|February 19, 2016
Retinal Nerve Fiber Layer Thinning in Alzheimer's Disease: A Case-Control Study in Comparison to Normal Aging, Parkinson's Disease, and Non-Alzheimer's DementiaJagan A Pillai, Robert Bermel, Aaron Bonner-Jackson, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|August 12, 2021
Ocrelizumab treatment for relapsing-remitting multiple sclerosis after a suboptimal response to previous disease-modifying therapy: A nonrandomized controlled trialBianca Weinstock-Guttman, Robert Bermel, Gary Cutter, et al.
Annals of Neurology|July 29, 2025
Volumetric MRI Comparing Longitudinal Change in MOGAD to NMOSD, MS and Healthy Controls, and Disability AssociationsAmy Kunchok, Moein Amin, Tatchaporn Ongphichetmetha, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|December 2, 2024
A digital version of the nine-hole peg test: Speed may be a more reliable measure of upper-limb disability than completion time in patients with multiple sclerosisXiaotong Jiang, Marisa McGinley, Joshua Johnston, et al.
Investigative Ophthalmology & Visual Science|June 4, 2018
Outer Retinal Assessment Using Spectral-Domain Optical Coherence Tomography in Patients With Alzheimer's and Parkinson's DiseaseAtsuro Uchida, Jagan A Pillai, Robert Bermel, et al.
Telemedicine Journal and E-Health : the Official Journal of the American Telemedicine Association|June 26, 2020
Implementation and Patient Experience of Outpatient TeleneurologyLindsay Ross, James Bena, Robert Bermel, et al.
Therapeutic Advances in Neurological Disorders|October 14, 2024
Long-term analysis of infections and associated risk factors in patients with multiple sclerosis treated with ocrelizumab: pooled analysis of 13 interventional clinical trialsTobias Derfuss, Robert Bermel, Chien-Ju Lin, et al.
Acta Neuropathologica Communications|June 15, 2022
Visual imaging as a predictor of neurodegeneration in experimental autoimmune demyelination and multiple sclerosisGabrielle M Mey, Kirsten S Evonuk, McKenzie K Chappell, et al.
Acta Neuropathologica Communications|July 15, 2022
Correction to: Visual imaging as a predictor of neurodegeneration in experimental autoimmune demyelination and multiple sclerosisGabrielle M Mey, Kirsten S Evonuk, McKenzie K Chappell, et al.
Pageof 3

Showing results (11-20 of 25) with videos related to

Sort By:
Pageof 3
Multiple Sclerosis (Houndmills, Basingstoke, England)|January 28, 2021
Characterisation of MS phenotypes across the age span using a novel data set integrating 34 clinical trials (NO.MS cohort): Age is a key contributor to presentationFrank Dahlke, Douglas L Arnold, Piet Aarden, et al.
American Journal of Alzheimer'S Disease and Other Dementias|February 19, 2016
Retinal Nerve Fiber Layer Thinning in Alzheimer's Disease: A Case-Control Study in Comparison to Normal Aging, Parkinson's Disease, and Non-Alzheimer's DementiaJagan A Pillai, Robert Bermel, Aaron Bonner-Jackson, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|August 12, 2021
Ocrelizumab treatment for relapsing-remitting multiple sclerosis after a suboptimal response to previous disease-modifying therapy: A nonrandomized controlled trialBianca Weinstock-Guttman, Robert Bermel, Gary Cutter, et al.
Annals of Neurology|July 29, 2025
Volumetric MRI Comparing Longitudinal Change in MOGAD to NMOSD, MS and Healthy Controls, and Disability AssociationsAmy Kunchok, Moein Amin, Tatchaporn Ongphichetmetha, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|December 2, 2024
A digital version of the nine-hole peg test: Speed may be a more reliable measure of upper-limb disability than completion time in patients with multiple sclerosisXiaotong Jiang, Marisa McGinley, Joshua Johnston, et al.
Investigative Ophthalmology & Visual Science|June 4, 2018
Outer Retinal Assessment Using Spectral-Domain Optical Coherence Tomography in Patients With Alzheimer's and Parkinson's DiseaseAtsuro Uchida, Jagan A Pillai, Robert Bermel, et al.
Telemedicine Journal and E-Health : the Official Journal of the American Telemedicine Association|June 26, 2020
Implementation and Patient Experience of Outpatient TeleneurologyLindsay Ross, James Bena, Robert Bermel, et al.
Therapeutic Advances in Neurological Disorders|October 14, 2024
Long-term analysis of infections and associated risk factors in patients with multiple sclerosis treated with ocrelizumab: pooled analysis of 13 interventional clinical trialsTobias Derfuss, Robert Bermel, Chien-Ju Lin, et al.
Acta Neuropathologica Communications|June 15, 2022
Visual imaging as a predictor of neurodegeneration in experimental autoimmune demyelination and multiple sclerosisGabrielle M Mey, Kirsten S Evonuk, McKenzie K Chappell, et al.
Acta Neuropathologica Communications|July 15, 2022
Correction to: Visual imaging as a predictor of neurodegeneration in experimental autoimmune demyelination and multiple sclerosisGabrielle M Mey, Kirsten S Evonuk, McKenzie K Chappell, et al.
Pageof 3